[O2-4] SARS2-5

[O2-4-13] Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the SARS-CoV-2 Omicron variants

*Yohei Seki¹, Kiyoko Nojima¹, Haruka Momose¹, Shuetsu Fukushi², Saya Moriyama ³, Yoshimasa Takahashi ³, Ken Maeda⁴, Tadaki Suzuki⁵, Takuo Mizukami¹, Yasuo Yoshihara⁶, Isao Hamaguchi¹ (1. Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, 2. Department of Virology 1, National Institute of Infectious Diseases, 3. Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 4. Department of Veterinary Science, National Institute of Infectious Diseases, 5. Department of Pathology, National Institute of Infectious Diseases, 6. National Hospital Organization Murayama Medical Center)